NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
YCBD
cbdMD, Inc.
YCBD has a slight edge over NVO overall, supported by stronger modeled upside.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
YCBD Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Strong |
YCBD's revenue and balance sheet are currently healthy, but its profitability and cash flow are weak.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
YCBD PE Valuation
YCBD has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
YCBD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
YCBD has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the stronger earnings trend. Trailing diluted EPS is up 4.9% for NVO versus YCBD down 100%.
YCBD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2024 | -$71.92 | +$66.48 |
| Q1 2024 | -$80.00 | +$247.12 |
| Q4 2023 | -$83.12 | +$266.08 |
| Q3 2023 | -$106.56 | +$339.84 |
| Q2 2023 | -$138.40 | +$246.80 |
| Q1 2023 | -$327.12 | -$147.12 |
| Q4 2022 | -$349.20 | -$118.80 |
| Q3 2022 | -$446.40 | -$277.20 |
YCBD lost $0.40 per share over the past year, a smaller loss than the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over YCBD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over YCBD on profitability, with a higher operating margin.
YCBD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $5.6M | +21% |
| Q1 2026 | $5.6M | +19% |
| Q4 2025 | $5M | -1.9% |
| Q3 2025 | $4.7M | +3.6% |
| Q2 2025 | $4.6M | -11% |
| Q1 2025 | $4.7M | +8.5% |
| Q4 2024 | $5.1M | -4.9% |
| Q3 2024 | $4.6M | -20% |
YCBD's revenue is recovering but still below its 2020 peak: $6M last quarter, up 21% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -20% | -0.7 points |
| Q1 2026 | -14% | -4 points |
| Q4 2025 | -5.7% | -4 points |
| Q3 2025 | -15% | -7.6 points |
| Q2 2025 | -20% | -12 points |
| Q1 2025 | -10% | +25 points |
| Q4 2024 | -1.7% | +18 points |
| Q3 2024 | -7% | +260 points |
YCBD's operating margin was −20% last quarter, down 0.7 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over YCBD on cash generation, producing positive trailing cash flow while its opponent burns cash.
YCBD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$460.2K | +$245.5K |
| Q3 2025 | -$243.6K | -255% |
| Q2 2025 | -$705.7K | -344% |
| Q3 2024 | $157.4K | +$541.1K |
| Q2 2024 | $289.8K | +$632.7K |
| Q1 2024 | -$699.4K | +$931.8K |
| Q4 2023 | -$290.5K | +$2M |
| Q3 2023 | -$383.7K | +$1.8M |
YCBD has burned cash in most quarters: −$2M over the past year, against −$957,967 the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over YCBD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
YCBD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.7% | +173K shares |
| 1 year | +1264% | +9.8M shares |
| 3 years | +6297% | +10.5M shares |
| 5 years | +10137% | +10.5M shares |
YCBD has 11M diluted shares, up 1264% from a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
YCBD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2020 | -0.4x | Net Cash |
| Q1 2020 | -1.6x | Net Cash |
YCBD has more cash than debt.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
YCBD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.9 | Neutral |
| Stochastic | 23.1 | Neutral |
YCBD's weekly RSI is 38 (neutral) and its Stochastic is 23 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
YCBD PE vs Healthcare Sector
YCBD has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over YCBD on trend strength, trading above more of its moving averages.
YCBD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.40 | 2.5% below |
| 20 week MA | $0.49 | 20% below |
| 50 week MA | $0.73 | 47% below |
| 100 week MA | $1.23 | 68% below |
| 200 week MA | $9.57 | 96% below |
YCBD is in a downtrend: it's below all five of its weekly moving averages, and 96% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over YCBD on returns for 2026, with the stronger performance.
YCBD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $932.4 | $1,123.2 | +20% |
| 2021 | $1,123.2 | $406.8 | -64% |
| 2022 | $406.8 | $90.0 | -78% |
| 2023 | $90.0 | $8.32 | -91% |
| 2024 | $8.32 | $3.02 | -64% |
| 2025 | $3.02 | $1.68 | -44% |
| 2026 YTD | $1.68 | $0.39 | -77% |
YCBD has finished five years in a row lower, and it's down 77% so far in 2026.